Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered serious bleeding events. Pharmaceutical organizations, including the makers of Xarelto, have a duty to ensure that their drugs are reasonably secure for use – and failure to accomplish so could be grounds for compensation. Our lawyers are functioning difficult to get those hurt by the drug the compensation they’re entitled to.
Even though bleeding is a widespread complication associated with anticoagulants, it has been alleged that xarelto is used for is much more unsafe than traditional blood thinners because no antidote exists to reverse its blood-thinning effects. This indicates that, in the event of an emergency, patients could be at threat for irreversible bleeding troubles, like life-threatening internal and gastrointestinal hemorrhaging.
Should you or even a loved 1 suffered a severe bleeding occasion following taking Xarelto, you may have legal recourse. For far more details, make contact with us today to have your case reviewed, cost-free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for previous and future health-related bills, lost wages, pain and suffering and, in cases of death, funeral costs. In addition, they’re seeking punitive damages, which are generally awarded to punish the defendant and deter other businesses from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is harmful and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective signifies of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs in the lawsuits allege serious and fatal injuries, which includes cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.
Xarelto is linked to significant bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing harmful clotting.
Visit this page for more details on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys inside the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.